Asset Management One Co. Ltd. raised its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 9.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 97,042 shares of the life sciences company's stock after purchasing an additional 8,299 shares during the quarter. Asset Management One Co. Ltd. owned 0.06% of Illumina worth $13,127,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Empowered Funds LLC lifted its position in shares of Illumina by 1.7% during the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company's stock valued at $516,000 after acquiring an additional 66 shares during the period. Caprock Group LLC grew its stake in shares of Illumina by 3.0% during the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company's stock valued at $376,000 after buying an additional 83 shares during the period. Integrated Advisors Network LLC grew its stake in shares of Illumina by 2.0% during the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company's stock valued at $585,000 after buying an additional 90 shares during the period. Stephens Inc. AR grew its stake in shares of Illumina by 1.4% during the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company's stock valued at $885,000 after buying an additional 90 shares during the period. Finally, Moors & Cabot Inc. boosted its position in Illumina by 1.7% during the 3rd quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company's stock worth $759,000 after purchasing an additional 95 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on ILMN. JPMorgan Chase & Co. upped their price target on shares of Illumina from $125.00 to $140.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. Piper Sandler upped their target price on shares of Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Morgan Stanley dropped their price objective on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 11th. Barclays lowered shares of Illumina from an "equal weight" rating to an "underweight" rating and dropped their price objective for the stock from $130.00 to $100.00 in a research note on Monday, February 10th. Finally, Royal Bank of Canada decreased their target price on shares of Illumina from $250.00 to $247.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Illumina currently has an average rating of "Moderate Buy" and an average price target of $159.45.
Read Our Latest Research Report on Illumina
Illumina Stock Performance
NASDAQ ILMN traded down $5.80 during midday trading on Thursday, hitting $97.20. The company had a trading volume of 5,941,966 shares, compared to its average volume of 2,542,587. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The stock has a market cap of $15.40 billion, a price-to-earnings ratio of -12.66, a P/E/G ratio of 1.67 and a beta of 1.10. The firm has a fifty day simple moving average of $129.96 and a two-hundred day simple moving average of $134.41. Illumina, Inc. has a fifty-two week low of $95.23 and a fifty-two week high of $156.66.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.
Illumina Company Profile
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Stories
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
